MedTrace Logo

Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.

NCT03539224 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2020-07-07

No results posted yet for this study

Summary

Phase IIa, open clinical trial, pilot, single arm and proof of concept.

Conditions

Interventions

DRUG

Dolutegravir (DTG)

DTG 50 mg tablet will be orally administered once daily with or without food upto 48 weeks

DRUG

Lamivudine (3TC)

Lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets. It will be orally administered once daily with or without food upto 48 weeks.

Sponsors & Collaborators

  • Instituto de Investigación Hospital Universitario La Paz

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-02
Primary Completion
2021-05-31
Completion
2021-07-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03539224 on ClinicalTrials.gov